Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2020 08:00 ET | Source: Biofrontera AG

Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.

Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with...
March 12, 2020 13:53 ET | Source: Biofrontera AG

Biofrontera AG extends subscription period for mandatory convertible bonds

Leverkusen, Germany, March 12, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds...
March 10, 2020 11:00 ET | Source: Biofrontera AG

European Commission approves use of Ameluz® for the treatment of actinic keratosis on extremities and trunk/neck

Leverkusen, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
March 03, 2020 06:00 ET | Source: Biofrontera AG

Biofrontera entered into binding term sheet with Maruho Co., Ltd.

Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered...
February 26, 2020 08:25 ET | Source: Biofrontera AG

Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds

Leverkusen, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory...
February 19, 2020 05:45 ET | Source: Biofrontera AG

Biofrontera provides clinical development updates

Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
February 03, 2020 05:45 ET | Source: Biofrontera AG

European Medicines Agency recommends indication expansion of Ameluz® for treatment of actinic keratoses on the extremities and trunk/neck

Leverkusen, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
January 31, 2020 11:38 ET | Source: Biofrontera AG

Organizational restructuring of Biofrontera and resignation of Chief Commercial Officer Christoph Dünwald

Leverkusen, Germany, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
January 14, 2020 00:30 ET | Source: Biofrontera AG

Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...
January 10, 2020 05:00 ET | Source: Biofrontera AG

Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right